HELP · Helus Pharma Inc.
Market Cap
$921.41M
Shares
73.07M
Volume · Oct 5
1.33M
Avg daily vol (3M)
1.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.70
Open$12.30
Day$11.52–12.30
52W close$3.87–14.02
Avg vol 30d1.7M
Short int3.2M · 4.4% float · 2.3d
Short vol30%
Last earningsNov 13, 2025
DataMar 2020–Oct 2026
Up next
call held Nov 13, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+88.4%
Trailing year
Short interest
4.4%
Latest settlement · 2.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+58%
above
Price vs 50-day avg
+0%
above
RSI (14)
44
neutral
MACD trend
Negative
52-week position
77%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+115%
trailing
YTD return
+43%
this year
Relative strength
+103%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +28 funds added
Insider flow
Accumulating
Net +$9.7M over 90 days · 0% sells
Short interest
Rising
4.42% of float · ▲ +6.8% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
99 holders — near 2-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+58%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
77%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $12 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +28 funds added
Insider flow
Accumulating
Net +$9.7M over 90 days · 0% sells
Short interest
Rising
4.42% of float · ▲ +6.8% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
99 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $12 · 77%
Range high $14
vs 200-day avg +58%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HELP
this stock
Helus Pharma Inc.
|
$921.41M | +43.0% | — | — | 4.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HELP | -7.2% | -0.6% | +115.5% | -4.8% | +43.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -7.0% | -0.1% | +103.3% | -5.7% | +30.2% |